about
Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA deliveryModulation of Bcl-x Alternative Splicing Induces Apoptosis of Human Hepatic Stellate Cells.Tumor extracellular acidity-activated nanoparticles as drug delivery systems for enhanced cancer therapy.Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles.Matrix metalloproteinase 2-responsive micelle for siRNA delivery.Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds.Synthesis of disulfide-cross-linked polypeptide nanogel conjugated with a near-infrared fluorescence probe for direct imaging of reduction-induced drug release.Surface charge switchable nanoparticles based on zwitterionic polymer for enhanced drug delivery to tumor.Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy.Single-step assembly of cationic lipid-polymer hybrid nanoparticles for systemic delivery of siRNA.Combating the drug resistance of cisplatin using a platinum prodrug based delivery system.Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery.A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy.Molecular Imaging of P-glycoprotein in Chemoresistant Tumors Using a Dual-Modality PET/Fluorescence Probe.RGD-Modified Albumin Nanoconjugates for Targeted Delivery of a Porphyrin Photosensitizer.A Redox-Activatable Fluorescent Sensor for the High-Throughput Quantification of Cytosolic Delivery of Macromolecules.Structure-activity relationships and cellular mechanism of action of small molecules that enhance the delivery of oligonucleotides.P-Glycoprotein-Targeted Photothermal Therapy of Drug-Resistant Cancer Cells Using Antibody-Conjugated Carbon NanotubesMultiarm Nanoconjugates for Cancer Cell-Targeted Delivery of Photosensitizers
P50
Q33587012-B3F64D3A-3F07-4127-B112-495EE70940EBQ37192466-A2155A59-D1B2-43D8-AB72-1F5BEC469CF4Q38128092-D964FCF6-A35C-40B0-973D-0633B6138F8BQ38976099-A64109A9-F129-42FF-A354-95B3BAA41369Q38984700-E8C14485-0976-4EED-9D26-711C6EFF85E6Q39075602-D50FA9EA-1C54-4025-9DCA-81761854FA2EQ39279680-82125642-A164-444C-A19D-09B5B52C048AQ39298856-42E0D50B-42D6-4F29-BAD1-97D82F04930AQ39319783-3EBE1706-303F-41A6-9A94-723211AED271Q39339823-D8525962-5ACF-46B1-8A17-BE308D0E75A7Q39341248-571CD017-79B7-41B3-A0A2-CE663C76EA58Q39460702-790C6125-C292-45C0-AFE0-F60389AA1209Q39601095-72409542-4ABE-4A5B-A66E-1201571555B9Q42798231-6D6716CE-A653-4D36-9B76-67FF95E12381Q42799162-799E2FD9-EB53-4640-9FCD-47BC9207AA44Q48898805-C70D663B-B707-454F-9BB3-92A83448A035Q55379950-0783B691-8F61-4092-ABA7-B2224BC51725Q57033051-D65AA91D-9844-4EF8-80E3-A1CD5589CE9EQ57728935-94934AE1-DF36-47C8-A353-4D1D61FB9C23
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Chengqiong Mao
@ast
Chengqiong Mao
@en
Chengqiong Mao
@es
Chengqiong Mao
@nl
type
label
Chengqiong Mao
@ast
Chengqiong Mao
@en
Chengqiong Mao
@es
Chengqiong Mao
@nl
prefLabel
Chengqiong Mao
@ast
Chengqiong Mao
@en
Chengqiong Mao
@es
Chengqiong Mao
@nl
P108
P106
P108
P1153
36970609400
P31
P496
0000-0002-3250-7733